NeoStem is building a dominant IP portfolio within the field of cell therapy to protect its cutting edge technologies. Notably, this patent estate includes composition of matter patents for AMR-001 and the Company’s T Regulatory Cell product candidate. Our patent estate includes composition of matter and method claims and a geographic breadth of filings. NeoStem’s IP portfolio focuses on immunology, cardiology, orthopedic, wound healing, stem cell isolation and purification, and VSELTM treatment indications.
CD34 Cell Program: Patents and Pending Patents
We have 6 granted or allowed U.S. patents and 10 granted or allowed O.U.S. patents covering AMR-001. We have 20 U.S. and O.U.S. patent applications pending. Specifically:
- U.S. Patent No. 7,794,705 covering a chemotactic stem cell product enriched for CD34+ cells that treats injury from AMI;
- U.S. Patent No. 8,088,370 covering the use of AMR-001 in the repair of injury caused by vascular insufficiency, including all forms of cardiac insufficiency, such as congestive heart failure, chronic myocardial ischemia and, we believe, vascular insufficiency induced ischemic conditions beyond the cardiac setting;
- U.S. Patent Nos. 8,343,485 and 8,425,899 offering expanded breadth in AMR’s composition and treatment methods in the vascular insufficiency setting.
- U.S. Continuation Application 13/295,240 and 13/685,585 expand range of cell concentration and serum components
T Regulatory Cell Program: Patents and Pending Patents
- Through exclusive world-wide licenses of over 30 issued patents and patent applications, we have secured the rights to a broad patent estate within the Treg field, covering natural Tregs (nTregs), induced Tregs (iTregs) and methods of treating or preventing certain conditions and/or diseases by use of Tregs.
VSELTM Technology Program: Pending Patents
- NeoStem continues prosecution of patent applications relating to methods of identifying and purifying its regenerative adult stem cell candidate (VSELs TM ) as well as methods of treating an array of maladies using VSELs, including cardiac repair, bone and cartilage regeneration, ocular disease and cutaneous wound healing.
Information accurate as of March 13, 2014.